BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 33971801)

  • 1. A 4-gene prognostic index for enhancing acute myeloid leukaemia survival prediction.
    Ortiz Rojas CA; Pereira-Martins DA; Bellido More CC; Sternadt D; Weinhäuser I; Hilberink JR; Coelho-Silva JL; Thomé CH; Ferreira GA; Ammatuna E; Huls G; Valk PJ; Schuringa JJ; Rego EM
    Br J Haematol; 2024 Apr; ():. PubMed ID: 38651345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A practical algorithm for acute myeloid leukaemia diagnosis following the updated 2022 classifications.
    Della Porta MG; Martinelli G; Rambaldi A; Santoro A; Voso MT
    Crit Rev Oncol Hematol; 2024 Apr; 198():104358. PubMed ID: 38615870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
    Wang F; Morita K; DiNardo CD; Furudate K; Tanaka T; Yan Y; Patel KP; MacBeth KJ; Wu B; Liu G; Frattini M; Matthews JA; Little LD; Gumbs C; Song X; Zhang J; Thompson EJ; Kadia TM; Garcia-Manero G; Jabbour E; Ravandi F; Bhalla KN; Konopleva M; Kantarjian HM; Andrew Futreal P; Takahashi K
    Nat Commun; 2021 May; 12(1):2607. PubMed ID: 33972549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia.
    Karnan S; Hanamura I; Ota A; Takasugi S; Nakamura A; Takahashi M; Uchino K; Murakami S; Wahiduzzaman M; Quang Vu L; Rahman ML; Hasan MN; Hyodo T; Konishi H; Tsuzuki S; Yoshikawa K; Suzuki S; Ueda R; Ejiri M; Hosokawa Y; Takami A
    Cell Death Discov; 2021 May; 7(1):121. PubMed ID: 34035227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.
    Zhu R; Li L; Nguyen B; Seo J; Wu M; Seale T; Levis M; Duffield A; Hu Y; Small D
    Signal Transduct Target Ther; 2021 May; 6(1):186. PubMed ID: 34024909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Collagen Type V α2 (COL5A2) in Colorectal Cancer is Associated with Poor Prognosis and Tumor Progression.
    Wang J; Jiang YH; Yang PY; Liu F
    Onco Targets Ther; 2021; 14():2991-3002. PubMed ID: 33981148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low expression of CHRDL1 and SPARCL1 predicts poor prognosis of lung adenocarcinoma based on comprehensive analysis and immunohistochemical validation.
    Deng H; Hang Q; Shen D; Zhang Y; Chen M
    Cancer Cell Int; 2021 May; 21(1):259. PubMed ID: 33980221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells
    Al-Ghabkari A; Narendran A
    Cancer Biol Ther; 2021 Apr; 22(4):333-344. PubMed ID: 33978549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNA LINC00649 regulates YES-associated protein 1 (YAP1)/Hippo pathway to accelerate gastric cancer (GC) progression via sequestering miR-16-5p.
    Wang H; Di X; Bi Y; Sun S; Wang T
    Bioengineered; 2021 Dec; 12(1):1791-1802. PubMed ID: 33975517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shengxuening Extracted from Silkworm Excrement Mitigates Myelosuppression via SCF-Mediated JAK2/STAT3 Signaling.
    Ding L; Tan Y; Xu L; Jin Y; Liu Y; Tu H; Zhang D; Wu B; Chen Y; Shen H; Liu L; Huang T; Zhou F
    Chem Biodivers; 2021 Jun; 18(6):e2100139. PubMed ID: 33973702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Precision diagnostics and therapy in hematological malignancies].
    Hellström Lindberg E; Cavelier L; Cammenga J; Andersson PO; Fioretos T; Rosenquist R
    Lakartidningen; 2021 May; 118():. PubMed ID: 33973223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRIG1 is a gatekeeper to exit from quiescence in adult neural stem cells.
    Marqués-Torrejón MÁ; Williams CAC; Southgate B; Alfazema N; Clements MP; Garcia-Diaz C; Blin C; Arranz-Emparan N; Fraser J; Gammoh N; Parrinello S; Pollard SM
    Nat Commun; 2021 May; 12(1):2594. PubMed ID: 33972529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations inhibiting KDM4B drive ALT activation in ATRX-mutated glioblastomas.
    Udugama M; Hii L; Garvie A; Cervini M; Vinod B; Chan FL; Das PP; Mann JR; Collas P; Voon HPJ; Wong LH
    Nat Commun; 2021 May; 12(1):2584. PubMed ID: 33972520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.
    Wang Y; Sinha S; Wellik LE; Secreto CR; Rech KL; Call TG; Parikh SA; Kenderian SS; Muchtar E; Hayman SR; Koehler AB; Van Dyke DL; Leis JF; Slager SL; Dong H; Kay NE; He R; Ding W
    Blood Cancer J; 2021 May; 11(5):86. PubMed ID: 33972504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of TARP correlates with inferior FLT3 mutations in non-adolescents and young adults with acute myeloid leukaemia.
    Shi Y; He Z; Bei L; Tao H; Ding B; Tao S; Wang C; Yu L
    Hematology; 2021 Dec; 26(1):380-387. PubMed ID: 33971801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Octamer-binding transcription factor 4 correlates with complex karyotype, FLT3-ITD mutation and poorer risk stratification, and predicts unfavourable prognosis in patients with acute myeloid leukaemia.
    Xiang Y; Zhou X
    Hematology; 2018 Dec; 23(10):721-728. PubMed ID: 29950146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.
    Marensi V; Keeshan KR; MacEwan DJ
    Biochem Pharmacol; 2021 Jan; 183():114348. PubMed ID: 33242449
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.